Dr. Reddy's Laboratories Limited (RDY)
NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 70.76 |
| Open | 70.72 |
| Bid | 68.97 x 900 |
| Ask | 73.23 x 800 |
| Day's range | 70.81 - 71.71 |
| 52-week range | 61.25 - 77.72 |
| Volume | |
| Avg. volume | 239,303 |
| Market cap | 11.97B |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | 17.85 |
| EPS (TTM) | 4.01 |
| Earnings date | 24 July 2024 - 29 July 2024 |
| Forward dividend & yield | 0.49 (0.68%) |
| Ex-dividend date | 07 July 2023 |
| 1y target est | 80.82 |
Business WireAurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities
HYDERABAD, India, June 03, 2024--Aurigene inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India.
Business WireDr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America
HYDERABAD, India, May 28, 2024--Dr. Reddy's Laboratories Ltd. today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America.
Business WireAlvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
HYDERABAD, India & REYKJAVIK, Iceland, May 21, 2024--Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva®.
© 2024 Yahoo. All rights reserved.